Extension of the applicable range of the implicit curve-fitting method for refrigerant thermodynamic properties to critical pressure

The method of implicit curve-fitting and explicit-calculation has been used for fast and stable calculations of thermodynamic properties of subcritical refrigerants. In order to extend that method to the critical pressure, a method of sectional implicit curve-fitting and explicit-calculation for refrigerant thermodynamic properties is introduced in this paper. The whole data range is divided into several subsections. The requirements on the continuity of thermodynamic properties and the first order derivative of thermodynamic properties in the intersection points of subsections are indicated, and the methods to meet the requirements are presented. Quadric equations are constructed instead of curve-fitting when no data can be given. With the source data obtained from REFPROP 7.1, explicit fast calculation formulae for thermodynamic properties of R410A, covering the saturated temperature of 213.15–344.51 K and superheat of 0–65 K, are given as an example. The calculation speeds of the formulae of R410A are more than 7000 times faster than those of REFPROP 7.1 while the total mean relative deviation of the fast calculation formulae from REFPROP 7.1 is only 0.04%.     

高岭土的活化及其地质聚合物的性能研究

研究了4种高岭土在不同煅烧条件下的活化及其地质聚合物的抗压强度和H4 交换容量的变化趋势.试验结果表明:产地相同的高岭土在800℃煅烧6 h后,所合成的地质聚合物的抗压强度和NH4 交换容量达到最大值;产地不同的高蛉土经相同条件煅烧后,所合成的地质聚合物的抗压强度和NH4 交换容量差异很大,这与高岭土的化学成分没有相关性,而与煅烧高岭土在碱溶液中的硅铝溶出率有相关性.     

The Role of Polymorphisms at the Interleukin-1, Interleukin-4, GATA-3 and Cyclooxygenase-2 Genes in Non-Surgical Periodontal Therapy

Periodontitis is a multifactorial disease. The aim of this explorative study was to investigate the role of Interleukin-(IL)-1, IL-4, GATA-3 and Cyclooxygenase-(COX)-2 polymorphisms after non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole) and subsequent maintenance in a Caucasian population. Analyses were performed using blood samples from periodontitis patients of a multi-center trial (ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00707369","term_id":"NCT00707369"}}NCT00707369=ABPARO-study). Polymorphisms were analyzed using quantitative real-time PCR. Clinical attachment levels (CAL), percentage of sites showing further attachment loss (PSAL) ≥1.3 mm, bleeding on probing (BOP) and plaque score were assessed. Exploratory statistical analysis was performed. A total of 209 samples were genotyped. Patients carrying heterozygous genotypes and single-nucleotide-polymorphisms (SNP) on the GATA-3-IVS4 +1468 gene locus showed less CAL loss than patients carrying wild type. Heterozygous genotypes and SNPs on the IL-1A-889, IL-1B +3954, IL-4-34, IL-4-590, GATA-3-IVS4 +1468 and COX-2-1195 gene loci did not influence CAL. In multivariate analysis, CAL was lower in patients carrying GATA-3 heterozygous genotypes and SNPs than those carrying wild-types. For the first time, effects of different genotypes were analyzed in periodontitis progression after periodontal therapy and during supportive treatment using systemic antibiotics demonstrating a slight association of GATA-3 gene locus with CAL. This result suggests that GATA-3 genotypes are a contributory but non-essential risk factor for periodontal disease progression.     

I2-Imidazoline Ligand CR4056 Improves Memory,Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice

Recent evidence suggests that I2-imidazoline ligands have neuroprotective properties in animal models of neurodegeneration, such as Alzheimer’s disease (AD). We recently demonstrated that the I2-ligand BU224 reversed memory impairments in AD transgenic mice and this effect was not because of reductions in amyloid-β (Aβ) deposition. In this study, our aim was to determine the therapeutic potential of the powerful analgesic I2-imidazoline ligand CR4056 in the 5xFAD model of AD, since this ligand has been proven to be safely tolerated in humans. Sub-chronic oral administration of CR4056 (30 mg/kg for 10 days) led to an improvement in recognition memory in 6-month-old 5xFAD mice, but not in wild-type littermates, without affecting Aβ levels or deposition. Our results also revealed a change in the profile of microglia by CR4056, resulting in a suppression of pro-inflammatory activated microglia, but increased the density of astrocytes and the expression of ApoE, which is mainly produced by these glial cells. In addition, CR4056 restored fibrinogen extravasation, affecting the distribution of markers of astrocytic end feet in blood vessels. Therefore, these results suggest that CR4056 protects against Aβ-mediated neuroinflammation and vascular damage, and offers therapeutic potential at any stage of AD.     

食用油碟式分离机碟片的渗氮激光相变硬化复合处理研究

介绍了食用油碟式分离机碟片的常规表面处理方法,提出了渗氮激光相变硬化复合处理技术,通过硬度实验、耐磨性实验、抗腐蚀性实验及残余应力分布曲线,对实验结果进行了较深入的分析,得出渗氮激光相变硬化复合处理技术可提高4C r13钢碟片抗腐蚀能力和抗疲劳性能的结论。     

Al4B2O9纳米棒改性制备优异综合性能的固体聚合物电解质

随着储能设备和电力驱动产品的激增,特别是电动汽车的大规模推广应用,全固态电池被认为是最有可能解决电动设备日益严峻的安全问题和高能量密度需求的策略之一.本文报道了一种Al4B2O9纳米棒改性的聚环氧乙烷(PEO)基固体聚合物电解质(ASPE),其具有高离子电导率、宽电化学窗口、良好的机械性能和阻燃性能.具体来说,因为Al...     

GFAAS法测定LiMn2O4中的Pb和Cd

采用石墨炉原子吸收光谱法(GFAAs)测定锂离子电池正极材料LiMn2O4中杂质Pb和Cd的含量.探讨了HNO2浓度、Pb和Cd的灰化温度和原子化温度、基体改进剂对测定结果的影响.该方法的操作简单,准确度高,Pb的回收率为91.22%～93.75%,Cd的回收率为96.5%～108.6%;精密度好,两种元素测定的相对标准偏差RSD(n=lO)<5%.     

Bile Acid–Drug Interaction via Organic Anion-Transporting Polypeptide 4C1 Is a Potential Mechanism of Altered Pharmacokinetics of Renally Excreted Drugs

Patients with liver diseases not only experience the adverse effects of liver-metabolized drugs, but also the unexpected adverse effects of renally excreted drugs. Bile acids alter the expression of renal drug transporters, however, the direct effects of bile acids on drug transport remain unknown. Renal drug transporter organic anion-transporting polypeptide 4C1 (OATP4C1) was reported to be inhibited by chenodeoxycholic acid. Therefore, we predicted that the inhibition of OATP4C1-mediated transport by bile acids might be a potential mechanism for the altered pharmacokinetics of renally excreted drugs. We screened 45 types of bile acids and calculated the IC₅₀, K_i values, and bile acid–drug interaction (BDI) indices of bile acids whose inhibitory effect on OATP4C1 was >50%. From the screening results, lithocholic acid (LCA), glycine-conjugated lithocholic acid (GLCA), and taurine-conjugated lithocholic acid (TLCA) were newly identified as inhibitors of OATP4C1. Since the BDI index of LCA was 0.278, LCA is likely to inhibit OATP4C1-mediated transport in clinical settings. Our findings suggest that dose adjustment of renally excreted drugs may be required in patients with renal failure as well as in patients with hepatic failure. We believe that our findings provide essential information for drug development and safe drug treatment in clinics.